4 March 2013Big Pharma

India rejects Bayer plea over compulsory licence

India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

More on this story

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

More on this story

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

More features

AbbVie blocks Humira antitrust suit

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

AstraZeneca suffers defeat over $7bn diabetes patent

US firm Brownstein nabs five from Crowell ‘at pivotal moment’

American Regent secures rare PI win in Hatch-Waxman dispute

WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

J&J sues over schizophrenia drug generic following patent victory